The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023

The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.

This new visiongain report describes India’s domestic as well as export market for pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly expanding market with a population of over a billion and a rapidly expanding economy. Prevalence values of many diseases are likely to increase with expansion of population, urbanisation and with higher identification rates in the coming decade. India's pharmaceutical market is increasingly important in global pharma, with both domestic and foreign companies benefiting. Healthcare provision - both public and private - is improving, leading to fast-expanding markets for healthcare products, especially modern pharmaceuticals, visiongain concludes.

Outsourcing for Contract Research and Manufacturing Services from India

The report also analyses India’s role in pharma outsourcing services. India is emerging as a competitive outsourcing hub and is playing a major role in the global pharmaceutical industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical companies are establishing long-term relationships with Indian manufacturing companies and contract research providers in India.

Generic drugs produced in India are increasingly being accepted worldwide, with leading companies such as Ranbaxy, Cipla and Dr. Reddy’s paving the way for others. Indian companies have increasingly taken on outsourced manufacturing for foreign clients, in addition to marketing pharmaceuticals themselves. There are also new drug development programmes by Indian companies, with eventual international market launches. Outsourcing to India has proven to be effective in saving costs and valuable developmental time. The Indian pharmaceutical industry has taken an important role in global pharma, not only as a manufacturer of generic drugs and APIs but also of new formulations.

Increasing costs for research and development and low productivity have compelled major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to lower-cost, developing nations such as India and China. India's emphasis on research and development and new drug discovery is growing. Furthermore, India is emerging as the preferred destination for outsourcing clinical trials, with both high quality and lower costs achieved there.

• With the introduction of ‘product patent regime’ in 2005, India is expected to receive further investment from international pharmaceutical companies in the years ahead
  
  
• Global pharmaceutical companies are establishing long-term relationships with Indian pharmaceutical companies and the contract manufacturing affiliates in India, in addition to establishing manufacturing, R&D and marketing bases there

Why You Should Buy This Report

In this report you will receive the following essential information for understanding the Indian pharma market and industry:

• The value of the Indian pharmaceutical market and its principal market segments from 2008 to 2023
  
  
• Exports values of the Indian pharmaceutical sector present and future
  
  
• Which current or future therapies that will drive the market for India’s pharmaceutical industry from 2008 to 2023
  
  
• Market drivers and restraints, including a comprehensive SWOT analysis
  
  
• Comprehensive views of key opinion leaders on Indian pharma
  
  
• The companies involved in the market and their business strategy
  
  
• What are the forecasts for sales for each of the therapeutic areas
  
  
• What is the present state of disease prevalence and future trends there
  
  
• What contract research and manufacturing opportunities exist for ‘new comers’

This Report is essential reading for the Following Professionals, Amongst Others:

• Investors in the India’s pharmaceutical industry
  
  
• Business managers of multinational companies
  
  
• Business managers of India’s domestic companies
  
  
• Business managers of pharmaceutical industry related to outsourcing
  
  
• Researchers, analysts and academics interested in India’s pharmaceutical industry
  
  
• Senior staff in healthcare authorities relevant to India

Unique Benefits When You Order This Report:

• Original primary research and analyses. You will not find this information anywhere else
  
  
• Full searchable report when you buy the company or corporate editions
  
  
• Copies can be printed off for offline reading
  
  
• Packed with charts, analysis, figures, graphs and tables

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. 
 

1 Executive Summary: India’s Pharmaceutical Sector 2008-2023

1.1 Prospects for India's Pharmaceutical Market

1.2 Aim, Scope and Format of the Report

2 Introduction to India's Pharmaceutical Sector

2.1 Historical Developments and Prospects for India's Pharmaceutical Sector

2.1.1 India's Early Years before 1970

2.1.2 Impetus for Increased Domestic Production 1970s

2.1.3 Development Phase 1980s and Growth Phase 1990s

2.1.4 Indian Pharmaceutical Industry Status in 2000s

2.3 Foreign Policy of India Related to Pharmaceutical Sector

2.4 India's GDP to Grow Significantly

2.5 India's Market Abroad

2.6 India's Purchasing Power Parity

2.7 Disease Epidemiology

2.7.1 Malaria

2.7.2 TB

2.7.3 HIV/AIDS

2.7.4 Pneumonia

2.7.5 Diarrhoea

2.7.6 Cancer

2.7.7 Cardiovascular Diseases

2.7.8 Diabetes

2.7.9 Asthma and Bronchitis

2.7.10 Neurological and Psychiatric Disorders and Addictions

2.8 Trend in Market for Individual Therapeutic Area

3 Analysis of the Indian Pharmaceutical Market

3.1 Pharmaceutical Market Analysis

3.2 Estimated Market Value for India's OTC Market

3.3 Estimated Market Value for India's Prescription Market

3.4 Estimated Market Volume for India's Generic Market

3.5 Branded Products Will Take Significant Market Share from 2008 to 2023

3.6 India's Major Selling Medicines

3.7 Sales Figure for Major Therapeutics Areas

3.8 Forecasts for Major Therapeutics Market: Anti-Infective

3.9 Forecasts for Major Therapeutics Market: Other Than Anti-Infective

3.10 Growth Rate in India's Therapeutic Market

4 Contract Manufacturing Businesses in India

4.1 Forecasts for Contract Manufacturing Services

4.2 Contract Manufacturing in India

4.2.1 Drivers for Contract Manufacturing for Outsourcing to India

4.3 Contract Manufacturing and Role of Indian Companies

4.3.1 Outsourcing for Generics

4.3.2 Sourcing Generics from Non-Competitors

4.3.3 Divi's Laboratories’ Business Model

4.3.4 Granules India for Production of Generic Prescription Medicines and OTCs

4.3.5 Matrix Contract Manufacturer for CNS Products

4.3.6 Neuland Focused on Anti-Bacterials

4.3.7 Natco Chose Chronic Diseases

4.4 Enforcing GMP Compliance for APIs in EU

4.5 Growth in Biotechnology Sector of India

4.5.1 Ranbaxy's Entry Into Biotechnology

5 Contract Research Businesses in India

5.1 Forecasts for Contract Research

5.2 Focus on Innovative R&D

5.3 CROs to Maintain High Quality

5.4 Drivers and Restrains for Outsourcing Clinical Research Services from India

5.5 Contract Research and Companies

5.5.1 R&D Investments by Foreign MNCs in India

5.5.2 Vimta is an Emerging Company

5.5.3 Suven is Emerging as a Contract R&D Focused

5.5.4 Wellquest is a CRO Compliant with International Regulatory Norms

5.6 Outsourcing Clinical Data Management

5.6.1 GlaxoSmithKline to Outsource Data Management

5.6.2 Clininvent is a CRO with Standardised Data Management Skills

5.7 Emerging Outsourcing Models

5.8 National Drug Authority to be Formed

5.9 Firsthand Interview for Expert Opinion on Clinical Research 1

5.9.1 Small and Medium Sized Companies Opt For CROs

5.9.2 Pros and Cons of Contract Research Services from India

5.9.3 India's Own Innovative Products

5.9.4 Differences between India and China for Undertaking Trials

5.10 Firsthand Interview for Expert Opinion on Clinical Research 2

5.10.1 Asian Nations with Proven Efficacy to Undertake Clinical Trials

5.11 Firsthand Interview for Expert Opinion on Clinical Research 3

5.11.1 Pros and Cons of Contract Research Services from India

6 India's Pharmaceutical Company Profile and Opportunities with Them

6.1 Suitable Business Models for Individual Pharmaceutical Companies in India

6.1.1 Merger and Acquisition (M&A) for Indian Companies

6.1.1.1 Dr Reddy Acquires Betapharm

6.1.2 Indian Pharmaceutical Companies Enter World Market

6.1.2.1 Zyday Cadila

6.1.2.2 Sun

6.1.2.3 Alkem

6.1.2.4 Wockhardt

6.1.2.5 Lupin

6.1.2.6 Ranbaxy

6.1.2.7 Cipla

6.1.3 Collaboration for Expansion and Improvement

6.1.4 Good Manufacturing Practice (GMP) Compliance

6.1.5 Foreign MNCs Maintain Significant Market Share in India

6.1.5.1 GlaxoSmithKline's Significant Market Share in India

6.1.5.2 Pfizer Emerged as the Most Significant Pharmaceutical Patent Applicant in India

7 SWOT Analysis for India's Pharmaceutical Market

7.1 The Existing Advantages of India's Pharmaceutical Sector

7.2 Vision for India's Pharmaceutical Sector

7.3 Goal of India's Pharmaceutical Sector

7.4 Visiongain Suggests Following Strategies for India’s Pharmaceutical Sector

7.5 Drivers and Restrain for India's Pharmaceutical Sector

7.6 India's Changing Demographic Profile

7.6.1 Public Healthcare System

7.6.2 Private Sector Contribution to Healthcare

7.6.3 Uneven Distribution of Healthcare

7.7 India's Pricing Pattern for Pharmaceutical Industry

7.7.1 Private Spending for Healthcare

7.7.2 Wholesale Distribution and Price Regulation

7.8 Firsthand Interview for Expert Opinion 1

7.8.1 Bureaucracy as Obstacles

7.8.2 Improving Access to Rural Areas

7.8.3 Therapeutic Areas to Get Increased Attention from 2008 to 2023

7.8.4 Drug Resistance for Antibiotics as Unmet Needs

7.9 Firsthand Interview for Expert Opinion 2

7.9.1 India's Key Strength

7.9.2 India's Edge Over China In Pharmaceutical Business

7.9.3 Need for Routine Inspection of Outsourcing Sites

7.9.4 Need for Creation of Economic Zone for Pharmaceutical Industry

7.9.5 Business Approach Needed for Rural Mass

7.9.6 India as an Emerging Market

7.9.7 Growth of India's Medical Tourism

7.9.8 Tropical Diseases Widespread in India

7.9.9 Vertical Integration Recommended for India's Companies

7.9.10 India's Emergence as a Major Pharmaceutical Market

8 Conclusions

8.1 India's Progress in Healthcare

8.2 Increases in Demand for Private Healthcare

8.3 Increases in Patient Demand for Service Provision

8.4 India's Progress in Pharmaceuticals and Outsourcing Services

8.5 Recommendations for India's Pharmaceutical Sector

8.6 Recommendations to Foreign Pharmaceutical Companies for India's Market

Tables

Table 1.1 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023

Table 3.1 Pharmaceutical Sales ($bn) of Top 20 Nations, 2006

Table 3.2 India's Total Pharmaceutical Sales ($m), 2008-2014

Table 3.3 India's Total Pharmaceutical Sales ($m), 2015-2023

Table 3.4 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023

Table 3.5 Forecasts for India's International OTC Market ($m), 2006- 2014

Table 3.6 Forecasts for India's International OTC Market ($m), 2015-2023

Table 3.7 Forecasts for India's Domestic OTC Market,($m), 2006-2014

Table 3.8 Forecasts for India's Domestic OTC Market ($m), 2015-2023

Table 3.9 Forecasts for India's Prescription Market ($m), 2006-2014

Table 3.10 Forecasts for India's Prescription Market ($m), 2015-2023

Table 3.11 Forecasts for Cephalosporins Sales ($m), 2006-2014

Table 3.12 Forecasts for Cephalosporins Sales( $m), 2015-2023

Table 3.13 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006-2014

Table 3.14 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015-2023

Table 3.15 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014

Table 3.16 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023

Table 3.17 Forecasts for Macrolides Sales ($m), 2006-2014

Table 3.18 Forecasts for Macrolides Sales ($m), 2015-2023

Table 3.19 Forecasts for Anti-Malarial Sales ($m), 2006-2014

Table 3.20 Forecasts for Anti-Malarial Sales($m), 2015-2023

Table 3.21 Forecasts for Anti-TB Sales ($m), 2006-2014

Table 3.22 Forecasts for Anti-TB Sales ($m), 2015 -2023

Table 3.23 Forecasts for Anti-Diarrhoeal Sales($m), 2006-2014

Table 3.24 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023

Table 3.25 Forecasts for Amoebicides Sales($m), 2006-2014

Table 3.26 Forecasts for Amoebicides Sales ($m), 2015-2023

Table 3.27 Forecasts for NSAID Sales ($m), 2006-2014

Table 3.28 Forecasts for NSAID Sales ($m), 2015-2023

Table 3.29 Forecasts for H2 Receptor Blockers Sales($m), 2006-2014

Table 3.30 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023

Table 3.31 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014

Table 3.32 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023

Table 3.33 Forecasts for Anti-Tussives Sales ($m), 2006-2014

Table 3.34 Forecasts for Anti-Tussives Sales ($m), 2015-2023

Table 3.35 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014

Table 3.36 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023

Table 3.37 Forecasts for Anti-Epileptics Sales ($m), 2006-2014

Table 3.38 Forecasts for Anti-Epileptics Sales ($m), 2015-2023

Table 3.39 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014

Table 3.40 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023

Table 3.41 Forecasts for Expectorants Sales ($m), 2006-2014

Table 3.42 Forecasts for Expectorants Sales ($m), 2015-2023

Table 3.43 Forecasts for Topical Corticosteroids Sales ($m), 2006-2014

Table 3.44 Forecasts for Topical Corticosteroids Sales ($m), 2015-2023

Table 3.45 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014

Table 3.46 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023

Table 3.47 Forecasts for Antacid Sales ($m), 2006-2014

Table 3.48 Forecasts for Antacid Sales ($m), 2015 -2023

Table 3.49 Forecasts for Calcium Sales ($m), 2006-2014

Table 3.50 Forecasts for Calcium Sales ($m), 2015 -2023

Table 3.51 Forecasts for Vitamin B Complex Sales ($m), 2006-2014

Table 3.52 Forecasts for Vitamin B Complex Sales ($m), 2015-2023

Table 3.53 Forecasts for Anti-Histamine Sales ($m), 2006-2014

Table 3.54 Forecasts for Anti-Histamine Sales ($m), 2015-2023

Table 3.55 Forecasts for Anti-Depressant Sales ($m), 2006-2014

Table 3.56 Forecasts for Anti-Depressant Sales ($m), 2015-2023

Table 4.1 Forecasts for India's Contract Manufacturing Revenues ($m), 2006-2014

Table 4.2 Forecasts for India's Contract Manufacturing Revenues ($m), 2015-2023

Table 5.1 Forecasts for India's Contract Research Revenues ($m), 2006-2014

Table 5.2 Forecasts for India's Contract Research Revenues( $m), 2015-2023

Table 5.3 Dr Reddy's Pipeline Strength

Table 6.1 Fastest Growing Local Companies from Top 50 in India

Table 6.2 Leading Local Companies from Top 100 in India

Table 6.3 Leading Corporate Groups

Table 6.4 Merger and Acquisition Activities of Indian Companies, 2007

Table 6.5 International M&A of Indian Firms

Table 7.1 SWOT Analysis for India's Pharmaceutical Sector

Table 7.2 India's Demographic Profile, 2007

Figures

Figure 1.1 Forecasts for India's Pharmaceutical Industry's Market ($m), 2008, 2013,2018 & 2023

Figure 2.1 Developments and Prospects for India's Pharmaceutical Sector (Past,Present & Future)

Figure 2.2 India's Pharmaceutical Industry Culture and Attributes Figure 3.1 Countries Ranked by Pharmaceutical Market Share, 2006

Figure 3.2 Ratio of Domestic Pharmaceutical Market Share by Value with Export,2006

Figure 3.3 India's Total Pharmaceutical Sales ($m), 2006-2014

Figure 3.4 India's Total Pharmaceutical Sales ($m), 2015-2023

Figure 3.5 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023

Figure 3.6 Forecasts for India's International OTC Market ($m), 2006-2014

Figure 3.7 Forecasts for India's International OTC Market ($m), 2015-2023

Figure 3.8 Forecasts for India's Domestic OTC Market ($m), 2006-2014

Figure 3.9 Forecasts for India's Domestic OTC Market ($m), 2015-2023

Figure 3.10 Ratio for Domestic and International OTC Market Share ($m), India, 2006

Figure 3.11 Forecasts for India's Prescription Market ($m), 2006-2014

Figure 3.12 Forecasts for India's Prescription Market ($m), 2015-2023

Figure 3.13 Proportion of India's Generic Market Share by Volume in Global Market,2008

Figure 3.14 Proportion of India's Generic Market Share by Volume in Global Market,2023

Figure 3.15 Ratio for Patent and Generic Market Share by Value, India, 2007

Figure 3.16 Ratio for Patent and Generic Market Share by Value, India, 2023

Figure 3.17 Major Anti-Infective Sales ($m), India, 2006

Figure 3.18 Major Selling Prescription Medicines Other Than Anti-Infective ($m),India, 2006

Figure 3.19 Major Selling OTC Medicines Other Than Anti-Infective ($m), India, 2006

Figure 3.20 Ratio of Anti-Infective to Other Medicines in the Market, India, 2008

Figure 3.21 Forecasts for Cephalosporins Sales ($m), 2006-2014

Figure 3.22 Forecasts for Cephalosporins Sales ($m), 2015-2023

Figure 3.23 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006- 2014

Figure 3.24 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023

Figure 3.25 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014

Figure 3.26 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023

Figure 3.27 Forecasts for Macrolides Sales ($m), 2006-2014

Figure 3.28 Forecasts for Macrolides Sales ($m), 2015-2023

Figure 3.29 Forecasts for Anti-Malarial Sales ($m), 2006-2014

Figure 3.30 Forecasts for Anti-Malarial Sales ($m), 2015-2023

Figure 3.31 Forecasts for Anti-TB Sales ($m), 2006-2014

Figure 3.32 Forecasts for Anti-TB Sales ($m), 2015 -2023

Figure 3.33 Forecasts for Anti-Diarrhoeal Sales ($m), 2006-2014

Figure 3.34 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023

Figure 3.35 Forecasts for Amoebicides Sales ($m), 2006-2014

Figure 3.36 Forecasts for Amoebicides Sales ($m), 2015-2023

Figure 3.37 Forecasts for NSAIDs Sales ($m), 2006-2014

Figure 3.38 Forecasts for NSAIDs Sales ($m), 2015-2023

Figure 3.39 Forecasts for H2 Receptor Blockers Sales ($m), 2006-2014

Figure 3.40 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023

Figure 3.41 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014

Figure 3.42 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023

Figure 3.43 Forecasts for Anti-Tussives Sales ($m), 2006-2014

Figure 3.44 Forecasts for Anti-Tussives Sales ($m), 2015-2023

Figure 3.45 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014

Figure 3.46 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023

Figure 3.47 Forecasts for Anti-Epileptics Sales ($m), 2006-2014

Figure 3.48 Forecasts for Anti-Epileptics Sales ($m), 2015-2023

Figure 3.49 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014

Figure 3.50 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023

Figure 3.51 Forecasts for Expectorants Sales ($m), 2006-2014

Figure 3.52 Forecasts for Expectorants Sales ($m), 2015-2023

Figure 3.53 Forecasts for Topical Corticosteroids Sales ($m), 2006- 2014

Figure 3.54 Forecasts for Topical Corticosteroids Sales ($m), 2015- 2023

Figure 3.55 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014

Figure 3.56 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023

Figure 3.57 Forecasts for Antacid Sales ($m), 2006-2014

Figure 3.58 Forecasts for Antacid Sales ($m), 2015 -2023

Figure 3.59 Forecasts for Calcium Sales ($m), 2006-2014

Figure 3.60 Forecasts for Calcium Sales ($m), 2015 -2023

Figure 3.61 Forecasts for Vitamin B Complex Sales ($m), 2006-2014

Figure 3.62 Forecasts for Vitamin B Complex Sales ($m), 2015-2023

Figure 3.63 Forecasts for Anti-Histamine Sales ($m), 2006-2014

Figure 3.64 Forecasts for Anti-Histamine Sales ($m), 2015-2023

Figure 3.65 Forecasts for Anti-Depressant Sales ($m), 2006-2014

Figure 3.66 Forecasts for Anti-Depressant Sales ($m), 2015-2023

Figure 3.67 Growth Rate According to Therapeutic Areas ($m), 2007

Figure 4.1 Forecasts for India's Contract Manufacturing Revenues ($m), 2008-2014

Figure 4.2 Forecasts for India's Contract Manufacturing Revenues ($m), 2015-2023

Figure 4.3 Path Up the Value Chain for Indian Companies

Figure 5.1 Forecasts for India's Contract Research Revenues ($m), 2008-2014

Figure 5.2 Forecasts for India's Contract Research Revenues ($m), 2015-2023

 
 

---

More Details

Organisations Mentioned in the Report:

Actavis

Alkem

Allen Spa

Agency National for Vigilance Sanitaire (ANVISA)

Advanced Medical Optics

AstraZeneca

Aurobindo

Avecia

Aventis

Betapharm

B-Tabs

Bulk Drug Manufacturers Association

Carbogen and Amcis

Central Drugs Standards Control Organisation (CDSCO)

Cipla

Clininvent

Dishman

Divi’s

Docpharma

Dr. Reddy's

Elder

Eli Lilly

Emcure

Ethimed

FDA

Geneva

GlaxoSmithKline

Government of India

Granules India

Hollister-Stier

Indian Drug Manufacturers’ Association

IMS Health

Ind-Swift

Intas

International Monetary Fund

Johnson & Johnson

Jubilant Organosys

Lupin

Macleods

Mankind

Matrix

Medicamenta

Medley

Medicines and Healthcare products Regulatory Agency (MHRA)

Medicines Control Council (MCC)

Mundogen

Mylan

Natco

National Institute of Pharmacy (NIP)

Negma

Neuland

Nicholas Piramal

Novartis

Novo Nordisk

Organisation of Pharmaceutical Producers of India (OPPI)

Perigo

Pfizer

Pharmaceutical Inspection Convention (PIC)

Pinewood

Quintiles

Ranbaxy

Rexcel

Rhodia

Roche

Sanmar API

Sanofi-Aventis

Shasun

Solvay

Sun

Suven

Taro

Tata Consulting Services

Terapia

Therapeutic Goods Administration (TGA)

Vimta

Wellquest

World Bank

Wockhardt

World Health Organisation (WHO)

World Trade Organization (WTO)

Zenotech

Zuventus

Zydus Cadila